Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA; BC2001 Investigators. James ND, et al. N Engl J Med. 2012 Apr 19;366(16):1477-88. doi: 10.1056/NEJMoa1106106. N Engl J Med. 2012. PMID: 22512481 Free article. Clinical Trial.
Organ preservation strategies in bladder cancer.
Hussain SA, James ND. Hussain SA, et al. Among authors: james nd. Expert Rev Anticancer Ther. 2002 Dec;2(6):641-51. doi: 10.1586/14737140.2.6.641. Expert Rev Anticancer Ther. 2002. PMID: 12503210 Review.
Molecular markers in bladder cancer.
Hussain SA, James ND. Hussain SA, et al. Among authors: james nd. Semin Radiat Oncol. 2005 Jan;15(1):3-9. doi: 10.1016/j.semradonc.2004.07.007. Semin Radiat Oncol. 2005. PMID: 15662601 Review.
Molecular pathways in bladder cancer: part 1.
Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Bryan RT, et al. Among authors: james nd. BJU Int. 2005 Mar;95(4):485-90. doi: 10.1111/j.1464-410X.2005.05325.x. BJU Int. 2005. PMID: 15705065 Review. No abstract available.
Molecular pathways in bladder cancer: part 2.
Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Bryan RT, et al. Among authors: james nd. BJU Int. 2005 Mar;95(4):491-6. doi: 10.1111/j.1464-410X.2005.05326.x. BJU Int. 2005. PMID: 15705066 Review. No abstract available.
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).
Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, Stott M, Robinson AC, James ND, Parmar MK, Dearnaley DP; Medical Research Council PR04 Collaborators. Mason MD, et al. Among authors: james nd. J Natl Cancer Inst. 2007 May 16;99(10):765-76. doi: 10.1093/jnci/djk178. J Natl Cancer Inst. 2007. PMID: 17505072 Clinical Trial.
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA. James ND, et al. Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29. Eur Urol. 2009. PMID: 19042080 Clinical Trial.
221 results